On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran, significantly reduces melanoma recurrence and spread in a phase 3 trial. Combining intismeran with Merck’s Keytruda showed notable improvements in patient outcomes, marking a pivotal… Read More »New mRNA vaccine cuts recurrence and spread of melanoma
A recent study reveals that an individualized mRNA vaccine for surgically resected melanoma, developed by Moderna and Merck, significantly reduces recurrence and distant spread risks over a five-year period. When combined with Keytruda, it boosts survival rates, showcasing the potential… Read More »Melanoma mRNA vaccine halves risk of recurrence, metastasis
HHS Secretary RFK Jr. has canceled over $500 million in mRNA vaccine funding, jeopardizing future vaccine development amidst ongoing health crises like bird flu. His anti-mRNA stance contradicts scientific evidence, risking delays in vital research. This decision threatens public health… Read More »RFK Jr cancels $500 million funding of mRNA vaccine research
Moderna and Merck report a 49% reduction in recurrence or death from melanoma with their new mRNA vaccine and KEYTRUDA combo, also cutting metastasis risk by 62%. This tailored immunotherapy is promising for melanoma treatment and prevention of reoccurrence, with… Read More »New mRNA vaccine for melanoma shows promising results
Merck and Moderna jointly announced the success of a new mRNA vaccine for melanoma has shown promising results in mid-stage clinical trials.